Claude B Sirlin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5573331/publications.pdf

Version: 2024-02-01

323 papers 35,782 citations

99 h-index 177 g-index

325 all docs

325 docs citations

325 times ranked

24645 citing authors

#	Article	IF	CITATIONS
1	CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis. Radiology, 2022, 302, 326-335.	7.3	32
2	Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease. European Radiology, 2022, 32, 2457-2469.	4.5	19
3	MR elastography in nonalcoholic fatty liver disease: inter-center and inter-analysis-method measurement reproducibility and accuracy at 3T. European Radiology, 2022, 32, 2937-2948.	4.5	12
4	Liver imaging: it is time to adopt standardized terminology. European Radiology, 2022, 32, 6291-6301.	4.5	13
5	Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD. Radiology, 2022, , 211131.	7.3	12
6	The Dose-Response Effects of Consuming High Fructose Corn Syrup-Sweetened Beverages on Hepatic Lipid Content and Insulin Sensitivity in Young Adults. Nutrients, 2022, 14, 1648.	4.1	8
7	Imaging of hepatocellular carcinoma: a pilot international survey. Abdominal Radiology, 2021, 46, 205-215.	2.1	4
8	Repeatability and accuracy of various region-of-interest sampling strategies for hepatic MRI proton density fat fraction quantification. Abdominal Radiology, 2021, 46, 3105-3116.	2.1	5
9	Linearity and Bias of Proton Density Fat Fraction as a Quantitative Imaging Biomarker: A Multicenter, Multiplatform, Multivendor Phantom Study. Radiology, 2021, 298, 640-651.	7.3	39
10	Abbreviated Magnetic Resonance Imaging for HCC Surveillance. Clinical Liver Disease, 2021, 17, 133-138.	2.1	6
11	Magnetic resonance elastography biomarkers for detection of histologic alterations in nonalcoholic fatty liver disease in the absence of fibrosis. European Radiology, 2021, 31, 8408-8419.	4.5	6
12	Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 513-527.	3.7	16
13	How to Use LI-RADS to Report Liver CT and MRI Observations. Radiographics, 2021, 41, 1352-1367.	3.3	13
14	Imaging Features at the Periphery: Hemodynamics, Pathophysiology, and Effect on LI-RADS Categorization. Radiographics, 2021, 41, 1657-1675.	3.3	7
15	Liver fibrosis imaging: A clinical review of ultrasound and magnetic resonance elastography. Journal of Magnetic Resonance Imaging, 2020, 51, 25-42.	3.4	53
16	Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 71, 849-860.	7.3	57
17	Normal range for MR elastography measured liver stiffness in children without liver disease. Journal of Magnetic Resonance Imaging, 2020, 51, 919-927.	3.4	23
18	Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. European Radiology, 2020, 30, 370-382.	4.5	55

#	Article	IF	CITATIONS
19	Hepatocellular adenomas: Understanding the pathomolecular lexicon, MRI features, terminology, and pitfalls to inform a standardized approach. Journal of Magnetic Resonance Imaging, 2020, 51, 1630-1640.	3.4	20
20	Deep convolutional neural network applied to the liver imaging reporting and data system (LI-RADS) version 2014 category classification: a pilot study. Abdominal Radiology, 2020, 45, 24-35.	2.1	28
21	Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid. European Radiology, 2020, 30, 1020-1030.	4.5	45
22	Does the Functional Liver Imaging Score Derived from Gadoxetic Acid–enhanced MRI Predict Outcomes in Chronic Liver Disease?. Radiology, 2020, 294, 98-107.	7.3	51
23	Accuracy of common proton density fat fraction thresholds for magnitude- and complex-based chemical shift-encoded MRI for assessing hepatic steatosis in patients with obesity. Abdominal Radiology, 2020, 45, 661-671.	2.1	16
24	Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance. Radiographics, 2020, 40, 1916-1931.	3.3	43
25	Editorial for "Interreader Agreement of Liver Imaging Reporting and Data System on MRI: A Systematic Review and Meta Analysisâ€, Journal of Magnetic Resonance Imaging, 2020, 52, 805-806.	3.4	3
26	The relationship between liver triglyceride composition and proton density fat fraction as assessed by 1 H MRS. NMR in Biomedicine, 2020, 33, e4286.	2.8	9
27	Deep learning assisted differentiation of hepatocellular carcinoma from focal liver lesions: choice of four-phase and three-phase CT imaging protocol. Abdominal Radiology, 2020, 45, 2688-2697.	2.1	37
28	Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. European Radiology, 2020, 30, 6003-6013.	4.5	43
29	Pediatric Hepatoblastoma, Hepatocellular Carcinoma, and Other Hepatic Neoplasms: Consensus Imaging Recommendations from American College of Radiology Pediatric Liver Reporting and Data System (LI-RADS) Working Group. Radiology, 2020, 296, 493-497.	7.3	42
30	Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat with Radiofrequency Ultrasound Data Using One-dimensional Convolutional Neural Networks. Radiology, 2020, 295, 342-350.	7.3	79
31	LI-RADS ancillary feature prediction of longitudinal category changes in LR-3 observations: an exploratory study. Abdominal Radiology, 2020, 45, 3092-3102.	2.1	9
32	Time to Clarify Common Misconceptions about the Liver Imaging Reporting and Data System for Contrast-enhanced US. Radiology, 2020, 295, 245-247.	7.3	12
33	Convolutional neural network-automated hepatobiliary phase adequacy evaluation may optimize examination time. European Journal of Radiology, 2020, 124, 108837.	2.6	6
34	Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US. Radiology, 2020, 295, 106-113.	7.3	57
35	Examining LI-RADS recommendations: should observation size only be measured on non-arterial phases?. Abdominal Radiology, 2020, 45, 3144-3154.	2.1	2
36	Prospective comparison of longitudinal change in hepatic proton density fat fraction (PDFF) estimated by magnitude-based MRI (MRI-M) and complex-based MRI (MRI-C). European Radiology, 2020, 30, 5120-5129.	4.5	2

#	Article	IF	CITATIONS
37	Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. Journal of Clinical Investigation, 2020, 130, 1453-1460.	8.2	362
38	LI-RADS ancillary features on contrast-enhanced ultrasonography. Ultrasonography, 2020, 39, 221-228.	2.3	13
39	Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection. Bosnian Journal of Basic Medical Sciences, 2020, 20, 401-410.	1.0	10
40	Reader agreement and accuracy of ultrasound features for hepatic steatosis. Abdominal Radiology, 2019, 44, 54-64.	2.1	16
41	Inter-reader agreement of magnetic resonance imaging proton density fat fraction and its longitudinal change in a clinical trial of adults with nonalcoholic steatohepatitis. Abdominal Radiology, 2019, 44, 482-492.	2.1	8
42	Pitfalls and problems to be solved in the diagnostic CT/MRI Liver Imaging Reporting and Data System (LI-RADS). European Radiology, 2019, 29, 1124-1132.	4.5	23
43	LI-RADS version 2018: What is new and what does this mean to my radiology reports?. Abdominal Radiology, 2019, 44, 41-42.	2.1	13
44	Image Annotation by Eye Tracking: Accuracy and Precision of Centerlines of Obstructed Small-Bowel Segments Placed Using Eye Trackers. Journal of Digital Imaging, 2019, 32, 855-864.	2.9	5
45	Editorial on the Current Role of Ultrasound. Applied Sciences (Switzerland), 2019, 9, 3512.	2.5	12
46	PS-186-Functional liver imaging score derived from gadoxetic acid-enhanced MRI predicts outcomes in patients with advanced chronic liver disease. Journal of Hepatology, 2019, 70, e115.	3.7	1
47	Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys. JAMA - Journal of the American Medical Association, 2019, 321, 256.	7.4	163
48	CT/MR LI-RADS 2018: clinical implications and management recommendations. Abdominal Radiology, 2019, 44, 1306-1322.	2.1	28
49	Liver Imaging Reporting and Data System Category 5: MRI Predictors of Microvascular Invasion and Recurrence After Hepatectomy for Hepatocellular Carcinoma. American Journal of Roentgenology, 2019, 213, 821-830.	2.2	56
50	User and system pitfalls in liver imaging with Llâ€RADS. Journal of Magnetic Resonance Imaging, 2019, 50, 1673-1686.	3.4	18
51	Measurement of spleen fat on MRI-proton density fat fraction arises from reconstruction of noise. Abdominal Radiology, 2019, 44, 3295-3303.	2.1	7
52	Role of US LI-RADS in the LI-RADS Algorithm. Radiographics, 2019, 39, 690-708.	3.3	45
53	MRI Assessment of Treatment Response in HIVâ€associated NAFLD: A Randomized Trial of a Stearoylâ€Coenzymeâ€Aâ€Desaturaseâ€1 Inhibitor (ARRIVE Trial). Hepatology, 2019, 70, 1531-1545.	7.3	33
54	Inter- and intra-reader agreement for gadoxetic acid–enhanced MRI parameter readings in patients with chronic liver diseases. European Radiology, 2019, 29, 6600-6610.	4.5	19

#	Article	IF	Citations
55	Is It Time to Expand the Definition of Washout Appearance in LI-RADS?. Radiology, 2019, 291, 658-659.	7.3	14
56	Longitudinal evolution of CT and MRI LI-RADS v2014 category 1, 2, 3, and 4 observations. European Radiology, 2019, 29, 5073-5081.	4.5	20
57	Relationship between resolution of nonâ€alcoholic steatohepatitis and changes in lipoprotein subâ€fractions: a postâ€hoc analysis of the <scp>PIVENS</scp> trial. Alimentary Pharmacology and Therapeutics, 2019, 49, 1205-1213.	3.7	24
58	Collagen Formation Assessed by Nâ€Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography. Hepatology, 2019, 70, 127-141.	7.3	21
59	<p>Ll-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance</p> . Journal of Hepatocellular Carcinoma, 2019, Volume 6, 49-69.	3.7	93
60	Pilot study on longitudinal change in pancreatic proton density fat fraction during a weightâ€loss surgery program in adults with obesity. Journal of Magnetic Resonance Imaging, 2019, 50, 1092-1102.	3.4	16
61	Inter-platform reproducibility of ultrasonic attenuation and backscatter coefficients in assessing NAFLD. European Radiology, 2019, 29, 4699-4708.	4.5	26
62	Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2019, 17, 1228-1238.	4.4	41
63	A Pilot Genomeâ€Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH. Hepatology Communications, 2019, 3, 1571-1584.	4.3	16
64	The Role of Preoperative Dynamic Contrast-enhanced 3.0-T MR Imaging in Predicting Early Recurrence in Patients With Early-Stage Hepatocellular Carcinomas After Curative Resection. Frontiers in Oncology, 2019, 9, 1336.	2.8	22
65	Surveillance of hepatocellular carcinoma by medical imaging. Quantitative Imaging in Medicine and Surgery, 2019, 9, 1904-1910.	2.0	9
66	Prevalence of Nonalcoholic Fatty Liver Disease in Children with Obesity. Journal of Pediatrics, 2019, 207, 64-70.	1.8	130
67	Monitoring Fatty Liver Disease with MRI Following Bariatric Surgery: A Prospective, Dual-Center Study. Radiology, 2019, 290, 682-690.	7.3	22
68	Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease. Gut, 2019, 68, 1884-1892.	12.1	48
69	Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (Llâ€RADS). Journal of Magnetic Resonance Imaging, 2019, 49, 1236-1252.	3.4	23
70	Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease. Journal of Magnetic Resonance Imaging, 2019, 49, 1456-1466.	3.4	28
71	Hepatic steatosis and reduction in steatosis following bariatric weight loss surgery differs between segments and lobes. European Radiology, 2019, 29, 2474-2480.	4.5	11
72	Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. Journal of Hepatology, 2019, 70, 133-141.	3.7	149

#	Article	IF	CITATIONS
73	Assessment of a highâ€SNR chemicalâ€shiftâ€encoded MRI with complex reconstruction for proton density fat fraction (PDFF) estimation overall and in the lowâ€fat range. Journal of Magnetic Resonance Imaging, 2019, 49, 229-238.	3.4	9
74	Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. Radiology, 2018, 286, 738-763.	7.3	215
75	Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018, 68, 723-750.	7.3	3,096
76	Llâ€RADS 2017: An update. Journal of Magnetic Resonance Imaging, 2018, 47, 1459-1474.	3.4	34
77	Repeatability and Reproducibility of the Ultrasonic Attenuation Coefficient and Backscatter Coefficient Measured in the Right Lobe of the Liver in Adults With Known or Suspected Nonalcoholic Fatty Liver Disease. Journal of Ultrasound in Medicine, 2018, 37, 1913-1927.	1.7	43
78	How to perform Contrast-Enhanced Ultrasound (CEUS). Ultrasound International Open, 2018, 04, E2-E15.	0.6	222
79	Noninvasive, Quantitative Assessment of Liver Fat by MRIâ€PDFF as an Endpoint in NASH Trials. Hepatology, 2018, 68, 763-772.	7.3	299
80	cHCCâ€CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology, 2018, 68, 113-126.	7.3	244
81	The LI-RADS adventure—a personal statement. Abdominal Radiology, 2018, 43, 1-2.	2.1	10
82	Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. Clinical Radiology, 2018, 73, 485-493.	1.1	63
83	LI-RADS: a glimpse into the future. Abdominal Radiology, 2018, 43, 231-236.	2.1	12
84	Epidemiology of Hepatic Steatosis at a Tertiary Care Center. Academic Radiology, 2018, 25, 317-327.	2.5	9
85	Liver fat imagingâ€"a clinical overview of ultrasound, CT, and MR imaging. British Journal of Radiology, 2018, 91, 20170959.	2.2	164
86	Letter to the editor response. Abdominal Radiology, 2018, 43, 239-239.	2.1	0
87	Randomised clinical trial: a leucineâ€metforminâ€sildenafil combination (<scp>NS</scp> â€0200) vs placebo in patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 1639-1651.	3.7	35
88	Link between gutâ€microbiome derived metabolite and shared geneâ€effects with hepatic steatosis and fibrosis in NAFLD. Hepatology, 2018, 68, 918-932.	7.3	141
89	Evidence Supporting LI-RADS Major Features for CT- and MR Imaging–based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. Radiology, 2018, 286, 29-48.	7.3	230
90	AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2018, 67, 358-380.	7.3	2,932

#	Article	IF	CITATIONS
91	LI-RADS and transplantation for hepatocellular carcinoma. Abdominal Radiology, 2018, 43, 193-202.	2.1	24
92	Crossâ€sectional correlation between hepatic R2* and proton density fat fraction (PDFF) in children with hepatic steatosis. Journal of Magnetic Resonance Imaging, 2018, 47, 418-424.	3.4	19
93	Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdominal Radiology, 2018, 43, 13-25.	2.1	338
94	LI-RADS® algorithm: CT and MRI. Abdominal Radiology, 2018, 43, 111-126.	2.1	39
95	Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study. European Radiology, 2018, 28, 1345-1355.	4.5	31
96	Interreader Reliability of LI-RADS Version 2014 Algorithm and Imaging Features for Diagnosis of Hepatocellular Carcinoma: A Large International Multireader Study. Radiology, 2018, 286, 173-185.	7.3	84
97	Technical report: gadoxetate-disodium-enhanced 2D R2* mapping: a novel approach for assessing bile ducts in living donors. Abdominal Radiology, 2018, 43, 1656-1660.	2.1	2
98	Nonstandardized Terminology to Describe Focal Liver Lesions in Patients at Risk for Hepatocellular Carcinoma: Implications Regarding Clinical Communication. American Journal of Roentgenology, 2018, 210, 85-90.	2.2	27
99	LI-RADS categories: concepts, definitions, and criteria. Abdominal Radiology, 2018, 43, 101-110.	2.1	33
100	Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology, 2018, 67, 858-872.	7.3	112
101	MRI proton density fat fraction is robust across the biologically plausible range of triglyceride spectra in adults with nonalcoholic steatohepatitis. Journal of Magnetic Resonance Imaging, 2018, 47, 995-1002.	3.4	27
102	Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and metaâ€analysis. Hepatology, 2018, 67, 401-421.	7. 3	329
103	Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. Abdominal Radiology, 2018, 43, 3-12.	2.1	47
104	Optimization of regionâ€ofâ€interest sampling strategies for hepatic MRI proton density fat fraction quantification. Journal of Magnetic Resonance Imaging, 2018, 47, 988-994.	3.4	20
105	CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI. Abdominal Radiology, 2018, 43, 127-142.	2.1	147
106	Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis. Radiology, 2018, 286, 486-498.	7.3	225
107	How bariatric surgery affects liver volume and fat density in NAFLD patients. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 1675-1682.	2.4	46
108	Cirrhosis and LI-RADS. Abdominal Radiology, 2018, 43, 26-40.	2.1	12

#	Article	IF	Citations
109	Hepatocarcinogenesis and LI-RADS. Abdominal Radiology, 2018, 43, 158-168.	2.1	29
110	Optimal threshold of controlled attenuation parameter with MRIâ€PDFF as the gold standard for the detection of hepatic steatosis. Hepatology, 2018, 67, 1348-1359.	7.3	250
111	Sources of systematic error in proton density fat fraction (PDFF) quantification in the liver evaluated from magnitude images with different numbers of echoes. NMR in Biomedicine, 2018, 31, e3843.	2.8	14
112	Management implications and outcomes of LI-RADS-2, -3, -4, and -M category observations. Abdominal Radiology, 2018, 43, 143-148.	2.1	15
113	LI-RADS Version 2018 Ancillary Features at MRI. Radiographics, 2018, 38, 1973-2001.	3.3	83
114	Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology, 2018, 289, 816-830.	7.3	634
115	Recommendation for terminology: Nodules without arterial phase hyperenhancement and with hepatobiliary phase hypointensity in chronic liver disease. Journal of Magnetic Resonance Imaging, 2018, 48, 1169-1171.	3.4	27
116	Current status of imaging in nonalcoholic fatty liver disease. World Journal of Hepatology, 2018, 10, 530-542.	2.0	166
117	White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI. Abdominal Radiology, 2018, 43, 2625-2642.	2.1	56
118	Responsiveness of controlled attenuation parameter (CAP) and its correlation with magnetic resonance imaging-proton density fat fraction (MRI-PDFF) in a multi-center clinical trial of subjects with nonalcoholic steatohepatitis (NASH). Journal of Hepatology, 2018, 68, S564.	3.7	0
119	Magnetic Resonance Elastography versus Transient Elastography in detection of fibrosis in nonalcoholic fatty liver disease: A systematic review and meta-analysis of individual participant date. Journal of Hepatology, 2018, 68, S560-S561.	3.7	1
120	Spectrum of Pitfalls, Pseudolesions, and Potential Misdiagnoses in Cirrhosis. American Journal of Roentgenology, 2018, 211, 87-96.	2.2	19
121	Inter-sonographer reproducibility of quantitative ultrasound outcomes and shear wave speed measured in the right lobe of the liver in adults with known or suspected non-alcoholic fatty liver disease. European Radiology, 2018, 28, 4992-5000.	4.5	29
122	Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantom. Magnetic Resonance in Medicine, 2017, 77, 1516-1524.	3.0	99
123	Effect of intravenous gadoxetate disodium and flip angle on hepatic proton density fat fraction estimation with six-echo, gradient-recalled-echo, magnitude-based MR imaging at 3T. Abdominal Radiology, 2017, 42, 1189-1198.	2.1	6
124	Adaptive local window for level set segmentation of CT and MRI liver lesions. Medical Image Analysis, 2017, 37, 46-55.	11.6	59
125	Bone marrow fat content is correlated with hepatic fat content in paediatric non-alcoholic fatty liver disease. Clinical Radiology, 2017, 72, 425.e9-425.e14.	1.1	14
126	Agreement between region-of-interest- and parametric map-based hepatic proton density fat fraction estimation in adults with chronic liver disease. Abdominal Radiology, 2017, 42, 833-841.	2.1	6

#	Article	IF	Citations
127	A Pilot Comparative Study of Quantitative Ultrasound, Conventional Ultrasound, and MRI for Predicting Histology-Determined Steatosis Grade in Adult Nonalcoholic Fatty Liver Disease. American Journal of Roentgenology, 2017, 208, W168-W177.	2.2	113
128	Quantifying Abdominal Adipose Tissue and Thigh Muscle Volume and Hepatic Proton Density Fat Fraction: Repeatability and Accuracy of an MR Imaging–based, Semiautomated Analysis Method. Radiology, 2017, 283, 438-449.	7.3	38
129	Liver histology and diffusionâ€weighted MRI in children with nonalcoholic fatty liver disease: A MAGNET study. Journal of Magnetic Resonance Imaging, 2017, 46, 1149-1158.	3.4	25
130	Assessment of treatment response in nonâ€elcoholic steatohepatitis using advanced magnetic resonance imaging. Alimentary Pharmacology and Therapeutics, 2017, 45, 844-854.	3.7	21
131	Effect of threshold growth as a major feature on LI-RADS categorization. Abdominal Radiology, 2017, 42, 2089-2100.	2.1	14
132	Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease. Hepatology, 2017, 66, 1474-1485.	7.3	103
133	Repeatability and reproducibility of 2D and 3D hepatic MR elastography with rigid and flexible drivers at end-expiration and end-inspiration in healthy volunteers. Abdominal Radiology, 2017, 42, 2843-2854.	2.1	34
134	Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. Gastroenterology, 2017, 153, 753-761.	1.3	209
135	Repeatability of MR Elastography of Liver: A Meta-Analysis. Radiology, 2017, 285, 92-100.	7.3	96
136	Accuracy of PDFF estimation by magnitudeâ€based and complexâ€based MRI in children with MR spectroscopy as a reference. Journal of Magnetic Resonance Imaging, 2017, 46, 1641-1647.	3.4	19
137	Elastography to assess the stage of liver fibrosis in children: Concepts, opportunities, and challenges. Clinical Liver Disease, 2017, 9, 5-10.	2.1	29
138	Screening and Surveillance of Hepatocellular Carcinoma. Radiologic Clinics of North America, 2017, 55, 1197-1209.	1.8	28
139	Application of Modified Spin-Echo–based Sequences for Hepatic MR Elastography: Evaluation, Comparison with the Conventional Gradient-Echo Sequence, and Preliminary Clinical Experience. Radiology, 2017, 282, 390-398.	7.3	46
140	Intravenous Gadoxetate Disodium Administration Reduces Breath-holding Capacity in the Hepatic Arterial Phase: A Multi-Center Randomized Placebo-controlled Trial. Radiology, 2017, 282, 361-368.	7.3	46
141	Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology, 2017, 42, 179-190.	2.1	113
142	Weight Loss Decreases Magnetic Resonance Elastography Estimated Liver Stiffness in Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 463-464.	4.4	29
143	In vivo triglyceride composition of abdominal adipose tissue measured by ¹ H MRS at 3T. Journal of Magnetic Resonance Imaging, 2017, 45, 1455-1463.	3.4	44
144	Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. Journal of Clinical Investigation, 2017, 127, 2697-2704.	8.2	137

#	Article	IF	CITATIONS
145	Liver Imaging Reporting and Data System: an expert consensus statement. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 29-39.	3.7	46
146	Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 – a review of important differences compared to the CT/MRI system. Clinical and Molecular Hepatology, 2017, 23, 280-289.	8.9	96
147	Accuracy and the effect of possible subjectâ€based confounders of magnitudeâ€based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference. Journal of Magnetic Resonance Imaging, 2016, 43, 398-406.	3.4	52
148	Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therapeutic Advances in Gastroenterology, 2016, 9, 692-701.	3.2	123
149	Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study. Hepatology, 2016, 64, 1547-1558.	7.3	64
150	Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. Journal of Hepatology, 2016, 65, 369-376.	3.7	264
151	Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial. Therapeutic Advances in Gastroenterology, 2016, 9, 152-161.	3.2	12
152	Imaging Outcomes of Liver Imaging Reporting and Data System Version 2014 Category 2, 3, and 4 Observations Detected at CT and MR Imaging. Radiology, 2016, 281, 129-139.	7.3	85
153	Liver Imaging Reporting and Data System: Review of Ancillary Imaging Features. Seminars in Roentgenology, 2016, 51, 301-307.	0.6	11
154	Nonâ€invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Alimentary Pharmacology and Therapeutics, 2016, 43, 83-95.	3.7	168
155	Magnetic resonance elastography identifies fibrosis in adults with alphaâ \in 1 antitrypsin deficiency liver disease: a prospective study. Alimentary Pharmacology and Therapeutics, 2016, 44, 287-299.	3.7	31
156	MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. Journal of Hepatology, 2016, 65, 1006-1016.	3.7	275
157	Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsyâ€proven nonalcoholic fatty liver disease: A prospective study. Hepatology, 2016, 63, 453-461.	7.3	168
158	How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma. Journal of Magnetic Resonance Imaging, 2016, 43, 1337-1345.	3.4	35
159	Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdominal Radiology, 2016, 41, 71-90.	2.1	163
160	Abdominal Pain in a Young Man with Oral Pigmentations. Journal of Emergency Medicine, 2016, 50, 335-336.	0.7	3
161	Staging of fibrosis in experimental non-alcoholic steatohepatitis by quantitative molecular imaging in rat models. Nuclear Medicine and Biology, 2016, 43, 179-187.	0.6	9
162	Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study. American Journal of Gastroenterology, 2016, 111, 986-994.	0.4	160

#	Article	IF	Citations
163	Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. European Radiology, 2016, 26, 1431-1440.	4.5	195
164	Cirrhotic liver: What's that nodule? The Llâ€RADS approach. Journal of Magnetic Resonance Imaging, 2016, 43, 281-294.	3.4	33
165	Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. European Radiology, 2016, 26, 674-682.	4.5	86
166	A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology, 2015, 62, 792-800.	7.3	276
167	Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for nonâ€invasive diagnosis of advanced fibrosis in biopsyâ€proven nonâ€alcoholic fatty liver disease: a prospective study. Alimentary Pharmacology and Therapeutics, 2015, 41, 1271-1280.	3.7	125
168	Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. Journal of Magnetic Resonance Imaging, 2015, 41, 1259-1267.	3.4	19
169	On confirmation bias in imaging research. Journal of Magnetic Resonance Imaging, 2015, 41, 1163-1164.	3.4	7
170	Reproducibility of MRâ€based liver fat quantification across field strength: Sameâ€day comparison between 1.5T and 3T in obese subjects. Journal of Magnetic Resonance Imaging, 2015, 42, 811-817.	3.4	67
171	Accuracy of multiecho magnitudeâ€based MRI (Mâ€MRI) for estimation of hepatic proton density fat fraction (PDFF) in children. Journal of Magnetic Resonance Imaging, 2015, 42, 1223-1232.	3.4	25
172	In vivo breathâ€hold ¹ H MRS simultaneous estimation of liver proton density fat fraction, and <i>T</i> ₁ and <i>T</i> ₂ of water and fat, with a multiâ€TR, multiâ€TE sequence. Journal of Magnetic Resonance Imaging, 2015, 42, 1538-1543.	3.4	32
173	Update on the Liver Imaging Reporting and Data System. Advances in Anatomic Pathology, 2015, 22, 314-322.	4.3	22
174	Evaluation of Liver Fibrosis Using Texture Analysis on Combined-Contrast-Enhanced Magnetic Resonance Images at 3.0T. BioMed Research International, 2015, 2015, 1-12.	1.9	28
175	Diagnostic Per-Patient Accuracy of an Abbreviated Hepatobiliary Phase Gadoxetic Acid–Enhanced MRI for Hepatocellular Carcinoma Surveillance. American Journal of Roentgenology, 2015, 204, 527-535.	2.2	105
176	Ultrasound Elastography and MR Elastography for Assessing Liver Fibrosis: Part 1, Principles and Techniques. American Journal of Roentgenology, 2015, 205, 22-32.	2.2	159
177	Ultrasound Elastography and MR Elastography for Assessing Liver Fibrosis: Part 2, Diagnostic Performance, Confounders, and Future Directions. American Journal of Roentgenology, 2015, 205, 33-40.	2.2	164
178	Accuracy of MR Imaging–estimated Proton Density Fat Fraction for Classification of Dichotomized Histologic Steatosis Grades in Nonalcoholic Fatty Liver Disease. Radiology, 2015, 274, 416-425.	7.3	239
179	Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2015, 13, 1513-1520.e1.	4.4	85
180	Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology, 2015, 61, 1239-1250.	7.3	296

#	Article	IF	CITATIONS
181	Effect of Weight Loss on Magnetic Resonance Imaging Estimation of Liver Fat and Volume in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2015, 13, 561-568.e1.	4.4	128
182	Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology, 2015, 61, 1887-1895.	7.3	138
183	Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based MRI for estimation of hepatic proton density fat fraction in overweight and obese children and adults. Abdominal Imaging, 2015, 40, 3070-3077.	2.0	57
184	Feasibility of and agreement between MR imaging and spectroscopic estimation of hepatic proton density fat fraction in children with known or suspected nonalcoholic fatty liver disease. Abdominal Imaging, 2015, 40, 3084-3090.	2.0	20
185	Diagnostic Accuracy of Preoperative Gadoxetic Acid–enhanced 3-T MR Imaging for Malignant Liver Lesions by Using Ex Vivo MR Imaging–matched Pathologic Findings as the Reference Standard. Radiology, 2015, 276, 775-786.	7.3	14
186	Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease andÂQuantification of Liver Fat Using a New Quantitative Ultrasound Technique. Clinical Gastroenterology and Hepatology, 2015, 13, 1337-1345.e6.	4.4	200
187	Associations between histologic features of nonalcoholic fatty liver disease (NAFLD) and quantitative diffusionâ€weighted MRI measurements in adults. Journal of Magnetic Resonance Imaging, 2015, 41, 1629-1638.	3.4	57
188	Hepatobiliary agents and their role in LI-RADS. Abdominal Imaging, 2015, 40, 613-625.	2.0	105
189	Cross-sectional and longitudinal evaluation of liver volume and total liver fat burden in adults with nonalcoholic steatohepatitis. Abdominal Imaging, 2015, 40, 26-37.	2.0	22
190	Llâ€RADS (Liver Imaging Reporting and Data System): Summary, discussion, and consensus of the Llâ€RADS Management Working Group and future directions. Hepatology, 2015, 61, 1056-1065.	7.3	412
191	Histogram Analysis of Hepatobiliary Phase MR Imaging as a Quantitative Value for Liver Cirrhosis: Preliminary Observations. Yonsei Medical Journal, 2014, 55, 651.	2.2	11
192	Spatial distribution of MRI-determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. Journal of Magnetic Resonance Imaging, 2014, 39, 1525-1532.	3.4	85
193	Effect of echoâ€sampling strategy on the accuracy of outâ€ofâ€phase and inâ€phase multiecho gradientâ€Echo MRI hepatic fat fraction estimation. Journal of Magnetic Resonance Imaging, 2014, 39, 567-575.	3.4	18
194	Effect of flip angle on the accuracy and repeatability of hepatic proton density fat fraction estimation by complex dataâ€based, T1â€independent, T2*â€corrected, spectrumâ€modeled MRI. Journal of Magnetic Resonance Imaging, 2014, 39, 440-447.	3.4	43
195	Accurate diagnosis of nonalcoholic fatty liver disease in human participants via quantitative ultrasound. , 2014, , .		16
196	Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjects. Journal of Magnetic Resonance Imaging, 2014, 39, 1265-1271.	3.4	47
197	Consensus report from the 6th International forum for liver MRI using gadoxetic acid. Journal of Magnetic Resonance Imaging, 2014, 40, 516-529.	3.4	40
198	Sebelipase alfa over 52weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. Journal of Hepatology, 2014, 61, 1135-1142.	3.7	81

#	Article	IF	Citations
199	Iron Deficiency in Patients With Nonalcoholic Fatty Liver Disease Is Associated With Obesity, Female Gender, and Low Serum Hepcidin. Clinical Gastroenterology and Hepatology, 2014, 12, 1170-1178.	4.4	34
200	Understanding LI-RADS. Magnetic Resonance Imaging Clinics of North America, 2014, 22, 337-352.	1.1	39
201	CT and MR Imaging Diagnosis and Staging of Hepatocellular Carcinoma: Part II. Extracellular Agents, Hepatobiliary Agents, and Ancillary Imaging Features. Radiology, 2014, 273, 30-50.	7. 3	430
202	CT and MR Imaging Diagnosis and Staging of Hepatocellular Carcinoma: Part I. Development, Growth, and Spread: Key Pathologic and Imaging Aspects. Radiology, 2014, 272, 635-654.	7.3	401
203	Evidence and Recommendations for Imaging Liver Fat in Children, Based on Systematic Review. Clinical Gastroenterology and Hepatology, 2014, 12, 765-773.	4.4	106
204	Quantification of liver iron with MRI: State of the art and remaining challenges. Journal of Magnetic Resonance Imaging, 2014, 40, 1003-1021.	3.4	208
205	LI-RADS Categorization of Benign and Likely Benign Findings in Patients at Risk of Hepatocellular Carcinoma: A Pictorial Atlas. American Journal of Roentgenology, 2014, 203, W48-W69.	2.2	43
206	Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI. Hepatic Oncology, 2014, 1, 95-105.	4.2	0
207	Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study. Hepatology, 2014, 60, 1920-1928.	7.3	388
208	Consensus Report of the Fifth International Forum for Liver MRI. American Journal of Roentgenology, 2013, 201, 97-107.	2.2	38
209	Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology, 2013, 58, 1930-1940.	7. 3	434
210	Association between novel <scp>MRI</scp> â€estimated pancreatic fat and liver histologyâ€determined steatosis and fibrosis in nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2013, 37, 630-639.	3.7	104
211	Evaluation of MRI fat fraction in the liver and spine pre and post SPIO infusion. Magnetic Resonance Imaging, 2013, 31, 1012-1016.	1.8	19
212	Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI. Expert Review of Gastroenterology and Hepatology, 2013, 7, 269-279.	3.0	39
213	Nonalcoholic Fatty Liver Disease: MR Imaging of Liver Proton Density Fat Fraction to Assess Hepatic Steatosis. Radiology, 2013, 267, 422-431.	7.3	410
214	Imaging-Based Diagnostic Systems for Hepatocellular Carcinoma. American Journal of Roentgenology, 2013, 201, 41-55.	2.2	61
215	Indeterminate Observations (Liver Imaging Reporting and Data System Category 3) on MRI in the Cirrhotic Liver: Fate and Clinical Implications. American Journal of Roentgenology, 2013, 201, 993-1001.	2.2	57
216	Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. Gastroenterology Research and Practice, 2013, 2013, 1-8.	1.5	42

#	Article	IF	CITATIONS
217	Estimation of Fish and ωâ€3 Fatty Acid Intake in Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2013, 57, 627-633.	1.8	35
218	Assessing liver fat fraction by ARFI induced shear wave attenuation: A preliminary result., 2013, , .		1
219	Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging. Journal of Magnetic Resonance Imaging, 2013, 37, 1359-1370.	3.4	68
220	Error model for reduction of cardiac and respiratory motion effects in quantitative liver DWâ€MRI. Magnetic Resonance in Medicine, 2013, 70, 1460-1469.	3.0	13
221	Protection from liver fibrosis by a peroxisome proliferator-activated receptor \hat{l} agonist. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1369-76.	7.1	136
222	Invited Commentary. Radiographics, 2012, 32, 1995-1998.	3.3	1
223	Hepatic Fat Quantification. Investigative Radiology, 2012, 47, 368-375.	6.2	98
224	Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y <i>HFE</i> mutations. Hepatology, 2012, 56, 1730-1740.	7.3	44
225	Focal hepatic lesions in Gd-EOB-DTPA enhanced MRI: the atlas. Insights Into Imaging, 2012, 3, 451-474.	3.4	69
226	Proton density fatâ€fraction: A standardized mrâ€based biomarker of tissue fat concentration. Journal of Magnetic Resonance Imaging, 2012, 36, 1011-1014.	3.4	385
227	Noninvasive classification of hepatic fibrosis based on texture parameters from double contrastâ€enhanced magnetic resonance images. Journal of Magnetic Resonance Imaging, 2012, 36, 1154-1161.	3.4	51
228	Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial. Hepatology, 2012, 56, 922-932.	7.3	218
229	Robustness of fat quantification using chemical shift imaging. Magnetic Resonance Imaging, 2012, 30, 151-157.	1.8	18
230	Cross-sectional investigation of correlation between hepatic steatosis and IVIM perfusion on MR imaging. Magnetic Resonance Imaging, 2012, 30, 572-578.	1.8	35
231	Correlation between liver histology and novel magnetic resonance imaging in adult patients with nonâ€alcoholic fatty liver disease – <scp>MRI</scp> accurately quantifies hepatic steatosis in <scp>NAFLD</scp> . Alimentary Pharmacology and Therapeutics, 2012, 36, 22-29.	3.7	285
232	Cardiac motion in diffusionâ€weighted MRI of the liver: artifact and a method of correction. Journal of Magnetic Resonance Imaging, 2012, 35, 318-327.	3.4	35
233	Quantification of Hepatic Steatosis with T1-independent, T2*-corrected MR Imaging with Spectral Modeling of Fat: Blinded Comparison with MR Spectroscopy. Radiology, 2011, 258, 767-775.	7.3	345
234	Amphicrine carcinoma of the liver. Annals of Diagnostic Pathology, 2011, 15, 355-357.	1.3	13

#	Article	IF	CITATIONS
235	Automated registration of sequential breath-hold dynamic contrast-enhanced MR images: a comparison of three techniques. Magnetic Resonance Imaging, 2011, 29, 668-682.	1.8	17
236	T ₁ independent, T ₂ [*] corrected chemical shift based fat–water separation with multiâ€peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. Journal of Magnetic Resonance Imaging, 2011, 33, 873-881.	3.4	183
237	Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. Journal of Magnetic Resonance Imaging, 2011, 34, 729-749.	3.4	613
238	Reproducibility of MRIâ€determined proton density fat fraction across two different MR scanner platforms. Journal of Magnetic Resonance Imaging, 2011, 34, 928-934.	3.4	130
239	Combination of complexâ€based and magnitudeâ€based multiecho waterâ€fat separation for accurate quantification of fatâ€fraction. Magnetic Resonance in Medicine, 2011, 66, 199-206.	3.0	166
240	<i>In vivo</i> characterization of the liver fat ¹ H MR spectrum. NMR in Biomedicine, 2011, 24, 784-790.	2.8	452
241	Constraining the initial phase in water–fat separation. Magnetic Resonance Imaging, 2011, 29, 216-221.	1.8	34
242	Diagnostic Challenges and Pitfalls in MR Imaging with Hepatocyte-specific Contrast Agents. Radiographics, 2011, 31, 1547-1568.	3.3	116
243	Estimation of Hepatic Proton-Density Fat Fraction by Using MR Imaging at 3.0 T. Radiology, 2011, 258, 749-759.	7.3	259
244	Science to Practice: Can T1ϕImaging Be Used to Diagnose and Assess the Severity of Hepatic Fibrosis?. Radiology, 2011, 259, 619-620.	7.3	18
245	Acetaminophen Pharmacokinetics in Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2011, 52, 198-202.	1.8	50
246	A Quantitative Approach to Sequence and Image Weighting. Journal of Computer Assisted Tomography, 2010, 34, 317-331.	0.9	13
247	Assessment of liver fat quantification in the presence of iron. Magnetic Resonance Imaging, 2010, 28, 767-776.	1.8	43
248	Gadoxetate Disodium–Enhanced MRI of the Liver: Part 2, Protocol Optimization and Lesion Appearance in the Cirrhotic Liver. American Journal of Roentgenology, 2010, 195, 29-41.	2.2	198
249	Apparent Diffusion Coefficient of Fibrosis and Regenerative Nodules in the Cirrhotic Liver at MRI. American Journal of Roentgenology, 2010, 194, 1515-1522.	2.2	11
250	Magnetic Resonance Imaging Quantification of Liver Iron. Magnetic Resonance Imaging Clinics of North America, 2010, 18, 359-381.	1.1	170
251	SAFETY Study: Alanine Aminotransferase Cutoff Values Are Set Too High for Reliable Detection of Pediatric Chronic Liver Disease. Gastroenterology, 2010, 138, 1357-1364.e2.	1.3	377
252	Gadoxetate Disodium–Enhanced MRI of the Liver: Part 1, Protocol Optimization and Lesion Appearance in the Noncirrhotic Liver. American Journal of Roentgenology, 2010, 195, 13-28.	2.2	313

#	Article	IF	Citations
253	Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review. Advances in Pediatrics, 2010, 57, 85-140.	1.4	40
254	Bone mineral density and atherosclerosis: The Multi-Ethnic Study of Atherosclerosis, Abdominal Aortic Calcium Study. Atherosclerosis, 2010, 209, 283-289.	0.8	49
255	Quantification of Liver Fat with Magnetic Resonance Imaging. Magnetic Resonance Imaging Clinics of North America, 2010, 18, 337-357.	1.1	260
256	CT and MRI of diffuse lobar involvement pattern in liver pathology. Diagnostic and Interventional Radiology, 2010, 17, 334-42.	1.5	12
257	Invited Commentary. Radiographics, 2009, 29, 1277-1280.	3.3	11
258	MR Imaging of Liver Fibrosis: Current State of the Art. Radiographics, 2009, 29, 1615-1635.	3.3	220
259	Capsular retraction: an uncommon imaging finding in hepatic inflammatory pseudotumour. British Journal of Radiology, 2009, 82, e256-e260.	2.2	15
260	Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology, 2009, 49, 809-820.	7.3	335
261	Quality of life in adults with nonalcoholic fatty liver disease: Baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology, 2009, 49, 1904-1912.	7.3	133
262	Advances in pediatric nonalcoholic fatty liver disease. Hepatology, 2009, 50, 1282-1293.	7.3	235
263	Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. Journal of Magnetic Resonance Imaging, 2009, 30, 145-152.	3.4	201
264	Effect of shot number on the calculated apparent diffusion coefficient in phantoms and in human liver in diffusionâ€weighted echoâ€planar imaging. Journal of Magnetic Resonance Imaging, 2009, 30, 547-553.	3.4	10
265	Nephrogenic systemic fibrosis in liver disease: A systematic review. Journal of Magnetic Resonance Imaging, 2009, 30, 1313-1322.	3.4	29
266	Noninvasive imaging biomarkers for steatosis assessment. Liver Transplantation, 2009, 15, 1389-1391.	2.4	7
267	Body MRI artefacts: from image degradation to diagnostic utility. Radiologia Medica, 2009, 114, 18-31.	7.7	8
268	Heritability of Nonalcoholic Fatty Liver Disease. Gastroenterology, 2009, 136, 1585-1592.	1.3	419
269	Nonalcoholic Fatty Liver Disease: Diagnostic and Fat-Grading Accuracy of Low-Flip-Angle Multiecho Gradient-Recalled-Echo MR Imaging at 1.5 T. Radiology, 2009, 251, 67-76.	7.3	287
270	Fatty Liver Disease: MR Imaging Techniques for the Detection and Quantification of Liver Steatosis. Radiographics, 2009, 29, 231-260.	3.3	246

#	Article	IF	CITATIONS
271	Noninvasive Assessment of Hepatic Steatosis. Clinical Gastroenterology and Hepatology, 2009, 7, 135-140.	4.4	129
272	Relaxation effects in the quantification of fat using gradient echo imaging. Magnetic Resonance Imaging, 2008, 26, 347-359.	1.8	356
273	Effects of intravenous gadolinium administration and flip angle on the assessment of liver fat signal fraction with opposedâ€phase and inâ€phase imaging. Journal of Magnetic Resonance Imaging, 2008, 28, 246-251.	3.4	22
274	Optimal phased-array combination for spectroscopy. Magnetic Resonance Imaging, 2008, 26, 847-850.	1.8	81
275	Review article: epidemiology, pathogenesis and potential treatments of paediatric nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2008, 28, 13-24.	3.7	124
276	Association of Coronary Artery and Aortic Calcium With Lumbar Bone Density: The MESA Abdominal Aortic Calcium Study. American Journal of Epidemiology, 2008, 169, 186-194.	3.4	140
277	Cirrhosis-associated Hepatocellular Nodules: Correlation of Histopathologic and MR Imaging Features. Radiographics, 2008, 28, 747-769.	3.3	176
278	Double-Contrast MRI for Accurate Staging of Hepatocellular Carcinoma in Patients with Cirrhosis. American Journal of Roentgenology, 2008, 190, 47-57.	2.2	58
279	Transient Homogeneously Enhancing Hepatic Masses: Can Size Predict Benignity?. American Journal of Roentgenology, 2008, 190, 300-307.	2.2	2
280	Vascular Contact With Soft Tissue. Journal of Computer Assisted Tomography, 2008, 32, 185-190.	0.9	3
281	Technology Insight: advances in liver imaging. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 215-228.	1.7	17
282	Cross-sectional Imaging of Extranodal Involvement in Abdominopelvic Lymphoproliferative Malignancies. Radiographics, 2007, 27, 1613-1634.	3.3	105
283	Radiogenomic Analysis to Identify Imaging Phenotypes Associated with Drug Response Gene Expression Programs in Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2007, 18, 821-830.	0.5	144
284	Superparamagnetic iron oxides and low molecular weight gadolinium chelates are synergistic for direct visualization of advanced liver fibrosis. Journal of Magnetic Resonance Imaging, 2007, 26, 728-737.	3.4	21
285	Decoding global gene expression programs in liver cancer by noninvasive imaging. Nature Biotechnology, 2007, 25, 675-680.	17.5	510
286	Acute appendicitis: diagnostic value of nonenhanced CT with selective use of contrast in routine clinical settings. European Radiology, 2007, 17, 2055-2061.	4.5	35
287	MR Contrast Agents for Liver Imaging: What, When, How. Radiographics, 2006, 26, 1621-1636.	3.3	144
288	Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, 413-427.	1.8	214

#	Article	IF	CITATIONS
289	Unusual cause of ureteral obstruction in transplant kidney. Abdominal Imaging, 2006, 31, 379-382.	2.0	30
290	Liver Fibrosis: Noninvasive Diagnosis with Double Contrast Material–enhanced MR Imaging. Radiology, 2006, 239, 425-437.	7.3	172
291	Fatty Liver: Imaging Patterns and Pitfalls. Radiographics, 2006, 26, 1637-1653.	3.3	362
292	Screening Sonography in Pregnant Patients With Blunt Abdominal Trauma. Journal of Ultrasound in Medicine, 2005, 24, 175-181.	1.7	56
293	CT appearance of the normal appendix in adults. European Radiology, 2005, 15, 2096-2103.	4.5	81
294	Abdominal Wall Hernias: Imaging Features, Complications, and Diagnostic Pitfalls at Multi–Detector Row CT. Radiographics, 2005, 25, 1501-1520.	3.3	230
295	CT Evaluation of Appendicitis and Its Complications: Imaging Techniques and Key Diagnostic Findings. American Journal of Roentgenology, 2005, 185, 406-417.	2.2	214
296	MRI of the Female Pelvis Using Vaginal Gel. American Journal of Roentgenology, 2005, 185, 1221-1227.	2.2	42
297	CT and MR Imaging of Extrahepatic Fatty Masses of the Abdomen and Pelvis: Techniques, Diagnosis, Differential Diagnosis, and Pitfalls. Radiographics, 2005, 25, 69-85.	3.3	356
298	Chest Radiography with a Flat-Panel Detector: Image Quality with Dose Reduction after Copper Filtration. Radiology, 2005, 237, 691-700.	7.3	43
299	Imaging Features of Perivascular Fatty Infiltration of the Liver: Initial Observations. Radiology, 2005, 237, 159-169.	7.3	98
300	Hypotensive Patients with Blunt Abdominal Trauma: Performance of Screening US. Radiology, 2005, 235, 436-443.	7.3	93
301	Whole-Body CT Screening: Spectrum of Findings and Recommendations in 1192 Patients. Radiology, 2005, 237, 385-394.	7.3	146
302	Ovarian imaging by magnetic resonance in obese adolescent girls with polycystic ovary syndrome: a pilot study. Fertility and Sterility, 2005, 84, 985-995.	1.0	56
303	Female Pelvis. Magnetic Resonance Imaging Clinics of North America, 2005, 13, 381-395.	1.1	8
304	Carotid Arteries: Contrast-enhanced US Angiographyâ€"Preliminary Clinical Experience. Radiology, 2004, 230, 561-568.	7.3	107
305	The Golden Hour: How to Spend Your Time and Money in Trauma Radiology. Radiology, 2004, 232, 622-624.	7.3	3
306	Blunt Abdominal Trauma: Clinical Value of Negative Screening US Scans. Radiology, 2004, 230, 661-668.	7.3	89

#	Article	IF	CITATIONS
307	Disproportionate Fat Stranding: A Helpful CT Sign in Patients with Acute Abdominal Pain. Radiographics, 2004, 24, 703-715.	3.3	180
308	Cisterna Chyli at Routine Abdominal MR Imaging: A Normal Anatomic Structure in the Retrocrural Space. Radiographics, 2004, 24, 809-817.	3.3	76
309	Gadolinium-DTPA-dextran: A macromolecular MR blood pool contrast agent1. Academic Radiology, 2004, 11, 1361-1369.	2.5	57
310	Screening Ultrasound in Blunt Abdominal Trauma. Journal of Intensive Care Medicine, 2003, 18, 253-260.	2.8	33
311	Screening US for Blunt Abdominal Trauma: Objective Predictors of False-Negative Findings and Missed Injuries. Radiology, 2003, 229, 766-774.	7.3	38
312	B-Mode Enhancement of the Liver with Microbubble Contrast Agent. Academic Radiology, 2001, 8, 734-740.	2.5	12
313	Contrast-enhanced B-mode US angiography in the assessment of experimental in vivo and in vitro atherosclerotic disease. Academic Radiology, 2001, 8, 162-172.	2.5	43
314	Importance of evaluating organ parenchyma during screening abdominal ultrasonography after blunt trauma Journal of Ultrasound in Medicine, 2001, 20, 577-583.	1.7	43
315	Quantification of fluid on screening ultrasonography for blunt abdominal trauma: a simple scoring system to predict severity of injury Journal of Ultrasound in Medicine, 2001, 20, 359-364.	1.7	26
316	Patterns of fluid accumulation on screening ultrasonography for blunt abdominal trauma: comparison with site of injury Journal of Ultrasound in Medicine, 2001, 20, 351-357.	1.7	23
317	Polydioxanone Biodegradable Pins in the Knee. American Journal of Roentgenology, 2001, 176, 83-90.	2.2	18
318	Blunt Abdominal Trauma: Screening US in 2,693 Patients. Radiology, 2001, 218, 352-358.	7.3	142
319	Shell Osteochondral Allografts of the Knee: Comparison of MR Imaging Findings and Immunologic Responses. Radiology, 2001, 219, 35-43.	7.3	105
320	US of Blunt Abdominal Trauma: Importance of Free Pelvic Fluid in Women of Reproductive Age. Radiology, 2001, 219, 229-235.	7.3	46
321	Predictors of Patient Response to Pulmonary Thromboendarterectomy. American Journal of Roentgenology, 2000, 174, 509-515.	2.2	68
322	Effect of acquisition rate on liver and portal vein enhancement with microbubble contrast. Ultrasound in Medicine and Biology, 1999, 25, 331-338.	1.5	32
323	Chronic thromboembolism: diagnosis with helical CT and MR imaging with angiographic and surgical correlation Radiology, 1997, 204, 695-702.	7.3	136